Track topics on Twitter Track topics that are important to you
The Regeneron Genetics Center (RGC) has surpassed 250,000 exomes sequenced since its creation three years ago—with a vision of sequencing up to double that number. RGC, a wholly-owned subsidiary of Regeneron Pharmaceuticals established in 2014, has increased its sequencing rate since then to 200,000 exomes per year, with plans to ramp up to between 400,000 to 500,000 people a year. “We were going to do 100,000 in five years, which means that we should have been at 60,000” by now, recalled George Yancopoulos, M.D., Ph.D., Regeneron co-founder, president and CSO. “We’re at 250,000, and pretty soon, we’ll be doing 500,000 a year. At our current rate, it would take us 10 years to do 5 million people—at the rate that we’re at pretty much now.” RGC is on track, he said, to sequence between 5 million and 10 million exomes over 10 years. “We have ...NEXT ARTICLE
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...